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In vitro Synergistic Activity of Sitafloxacin in Combination With
Background. Multidrug-resistant Acinetobacter baumannii (MDR-AB) is a major cause of nosocomial infections, and associated with high mortality rate. The objective of this study was to test synergistic effect of sitafloxacin and colistin against MDR-AB clinical isolates in Thailand.
Methods. The synergistic effect of sitafloxacin in combination with colistin against the 264 MDR-AB clinical isolates from 13 tertiary care hospitals in Thailand were tested. The fractional inhibitory concentration index (FICI) of combination was determined using the checkerboard method according to CLSI 2016. Time-kill assays were performed for 2 strains (H25 and K21) using sitafloxacin alone and in combination with colistin.
Results. The MICs of sitafloxacin and colistin range from 0.0156 to 8 µg/mL, and 0.5-16 µg/mL, respectively. The results of synergy testing for the 264 MDR-AB isolates are shown in Table 1 . Sitafloxacin reduced the MIC of colistin 2-fold to 8-fold from the original concentrations (Figure 1) . From 43 colistin-resistant isolates in combination tested, 39 isolates (90.7%) become susceptible to colistin. In the timekill assay, synergistic effects were found for two isolates in all concentrations tested, and bactericidal activity was observed within 4 hours and maintained over 24 hours (Figures 2 and 3) .
Conclusion. The synergistic effect of sitafloxacin and colistin combination was found. Most of isolates had at least a 2-fold decrease in MIC of colistin, which could be implied to reduce dose of colistin 50% from regular dose. Sitafloxacin combined with colistin may be benefit for alternative treatment of MDR-AB infections. 
